{
    "nct_id": "NCT03605927",
    "official_title": "CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease",
    "inclusion_criteria": "* Hematologic malignancy or blood disorder requiring allogeneic HCT\n* Adequate vital organ function as defined per protocol\n* Karnofsky Performance Status Score (KPS) â‰¥ 80%\n* Participants must have an available 8/8 HLA-A, -B, -C, and -DRB1 matched-related or unrelated donor\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active infection not controlled with appropriate antimicrobial therapy\n* HIV, hepatitis B or C infection or known history of HIV, hepatitis B or C(all patients will be tested for HIV, hepatitis B and C as part of standard pre-transplant testing, and will be excluded from this trial if positive)\n* Anti-thymocyte globulin, or cyclophosphamide administered within 14 days before or planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days after HCT\n* Known allergic reactions to components of the study drug\n* Concurrent treatment with another investigational drug\n* History of thromboembolism, transient ischemic attack, stroke, myocardial infarction within 3 months preceding the transplant, or uncontrolled congestive heart failure or cardiac arrhythmias.\n* Post-transplant maintenance therapies such as FLT3 inhibitor, tyrosine kinase inhibitor, JAK inhibitors etc. are not allowed if plan is to initiate such therapies <90 days post-transplant. Patient will be eligible if plan to initiate maintenance therapy is after day 90 post-transplant.",
    "miscellaneous_criteria": ""
}